800 related articles for article (PubMed ID: 19233073)
1. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Singh A
Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
[TBL] [Abstract][Full Text] [Related]
4. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
6. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
7. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation.
Adamson JW
Adv Chronic Kidney Dis; 2009 Mar; 16(2):76-82. PubMed ID: 19233066
[TBL] [Abstract][Full Text] [Related]
8. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
9. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
10. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K
Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
[TBL] [Abstract][Full Text] [Related]
11. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
13. [Issues related to iron replacement in dialyzed patients].
Kessler M
Nephrol Ther; 2006 Sep; 2 Suppl 4():S266-73. PubMed ID: 17373269
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of iron deficiency in predialysis state by low molecular weight iron dextran high doses intravenously].
Fievet P; Coppin M; Brazier F; Lefèvre M; Stephan R; Demontis R
Nephrol Ther; 2012 Feb; 8(1):41-6. PubMed ID: 21684231
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
17. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
Besarab A; Dalton CL
Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
[TBL] [Abstract][Full Text] [Related]
18. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
19. Assessing iron status: beyond serum ferritin and transferrin saturation.
Wish JB
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
[TBL] [Abstract][Full Text] [Related]
20. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?
Kalantar-Zadeh K; Kalantar-Zadeh K; Lee GH
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S9-18. PubMed ID: 17699375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]